Genmab Reports Safety Data for Rina-S and Bevacizumab in Ovarian Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy GMAB?
Genmab announced new data demonstrating that rinatabart sesutecan, an investigational folate receptor alpha-targeted, topoisomerase I inhibitor antibody-drug conjugate, evaluated in combination with bevacizumab in patients with advanced ovarian cancer, showed a safety profile consistent with the known safety profiles of Rina-S and bevacizumab. These data are from the combination therapy cohort D2 of the multi-part Phase 1/2 RAINFOL-01 study and were presented during an oral session at the 2026 Society of Gynecologic Oncology Annual Meeting on Women's Cancer in San Juan, Puerto Rico. "Advanced ovarian cancer is a complex and difficult-to-treat disease, and the ability for investigational therapies such as Rina-S to be safely combined with bevacizumab can provide clinicians with more options to help improve disease control and manage resistance," said Cara Mathews, study investigator and Associate Professor, Obstetrics and Gynecology at the Women and Infants Hospital, Brown University. "Rina-S has shown a manageable safety profile as a monotherapy, and these safety data suggest that it may be combined with a standard-of-care therapy such as bevacizumab without significantly increasing the risk of additional side effects." As of data cutoff, 40 patients with recurrent ovarian cancer had received Rina-S plus bevacizumab every three weeks until disease progression or unacceptable toxicity. The primary endpoint was safety and tolerability. The combination of Rina-S and bevacizumab was tolerable, with manageable adverse events. The safety profile of the combination was consistent with the known safety profiles of the individual agents, with no new or unexpected safety signals. The most common treatment-emergent AEs included nausea, fatigue, anemia, and neutropenia. No safety signals of ocular toxicities, peripheral neuropathy or interstitial lung disease were reported, and no clinically significant bleeding was observed. Serious TEAEs occurred in six patients, and TEAEs leading to Rina-S dose reductions occurred in 11 patients. Rina-S and bevacizumab discontinuation occurred in two patients. No fatal TEAEs were reported.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 27.910
Low
26.00
Averages
38.50
High
48.00
Current: 27.910
Low
26.00
Averages
38.50
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genmab Major Shareholder Announcement
- Shareholder Stake: As of April 13, 2026, Orbis Investment Management Limited controls 3,114,318 shares in Genmab A/S, representing 4.85% of the company's share capital and voting rights, highlighting its significant role in corporate governance.
- Company Overview: Genmab is an international biotechnology firm dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, boasting over 25 years of experience and a diverse range of antibody therapeutic formats, showcasing its robust R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a strong late-stage clinical pipeline aimed at delivering transformative medicines to patients, which not only enhances the company's market competitiveness but also lays the groundwork for future revenue growth.
- Global Presence: Headquartered in Copenhagen, Denmark, Genmab has an international footprint across North America, Europe, and Asia Pacific, reflecting its strategic implementation of a global strategy to capture growth opportunities in the global biopharmaceutical market.
See More
Genmab's DARZALEX Global Sales Reach $3.96 Billion
- Strong Sales Performance: Genmab reported that its multiple myeloma therapy DARZALEX achieved worldwide net sales of $3.96 billion in Q1, with U.S. sales contributing $2.208 billion and international markets generating $1.756 billion, indicating robust global demand for the product.
- Positive Market Reaction: Genmab's stock traded approximately 2% higher during pre-market hours, reflecting investor optimism regarding the company's sales growth and further solidifying its market position in the biopharmaceutical sector.
- Product Diversification: The sales figures include both intravenous and subcutaneous formulations, with the latter marketed in the U.S. as DARZALEX FASPRO, demonstrating the company's innovation in product forms to meet diverse patient needs.
- Industry Context: Despite pressures on the healthcare sector due to disruptions in the Middle East, Genmab stands out among oversold healthcare stocks above $10 billion, showcasing its product resilience and competitive strength in the market.
See More
Genmab Reports $3.964 Billion DARZALEX® Sales in Q1 2026
- Strong Sales Performance: In Q1 2026, Genmab reported worldwide net sales of DARZALEX® totaling $3.964 billion, with $2.208 billion from the U.S. and $1.756 billion from the rest of the world, indicating robust demand and growth potential for the product in global markets.
- Royalty Revenue: Genmab benefits from royalties on DARZALEX sales through its exclusive global licensing agreement with Johnson & Johnson, which not only provides a stable revenue stream but also strengthens its market position in the biopharmaceutical sector.
- Innovative Drug Development: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines, showcasing its R&D capabilities and competitive edge in biotechnology, which is expected to drive future revenue growth.
- Global Market Presence: As an international biotechnology company, Genmab has established operations across North America, Europe, and Asia Pacific, and this global strategy enhances its market reach while providing ample opportunities for future expansion and growth.
See More
Safety Study of Rina-S and Bevacizumab Combination Therapy
- Clinical Trial Results: The RAINFOL™-01 trial demonstrated that the combination of Rina-S and bevacizumab was well-tolerated in 40 patients with advanced ovarian cancer, with no new safety signals, indicating potential for broader clinical treatment options.
- Adverse Event Analysis: Common treatment-emergent adverse events included nausea (80%), fatigue (67.5%), anemia (55%), and neutropenia (45%), providing critical safety data for future treatment regimens.
- Research Significance: Investigator Dr. Cara Mathews noted that the safety profile of Rina-S aligns with that of bevacizumab, potentially offering more effective disease control options for ovarian cancer patients, particularly in resistant cases.
- Future Development Directions: Genmab plans to further evaluate the efficacy of this combination therapy in the upcoming Phase 3 RAINFOL-04 trial, showcasing the company's ongoing commitment and innovative potential in ovarian cancer treatment.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Genmab Major Shareholder Announcement
- Shareholder Ownership: As of March 27, 2026, Orbis Investment Management Limited controls 3,205,763 shares in Genmab A/S, representing 4.99% of the company's share capital and voting rights, indicating its significant influence in corporate governance.
- Investment Management Background: Orbis Investment Management Limited is a well-known investment management firm, and its increased stake may impact Genmab's strategic decisions and market performance, reflecting investor confidence in the company's future growth.
- Company Overview: Established in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on improving the lives of cancer and serious disease patients through innovative antibody medicines, having received approvals for eight antibody drugs, showcasing its strong R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a robust late-stage clinical pipeline aimed at delivering transformative medicines to patients, and with the growing demand for biopharmaceuticals, the company's market outlook appears promising.
See More
Genmab Major Shareholder Announcement
- Shareholder Stake: As of April 13, 2026, Orbis Investment Management Limited controls 3,114,318 shares in Genmab A/S, representing 4.85% of the company's share capital and voting rights, highlighting its significant role in corporate governance.
- Company Overview: Genmab is an international biotechnology firm dedicated to improving the lives of cancer and serious disease patients through innovative antibody medicines, boasting over 25 years of experience and a diverse range of antibody therapeutic formats, showcasing its robust R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a strong late-stage clinical pipeline aimed at delivering transformative medicines to patients, which not only enhances the company's market competitiveness but also lays the groundwork for future revenue growth.
- Global Presence: Headquartered in Copenhagen, Denmark, Genmab has an international footprint across North America, Europe, and Asia Pacific, reflecting its strategic implementation of a global strategy to capture growth opportunities in the global biopharmaceutical market.
See More
Genmab's DARZALEX Global Sales Reach $3.96 Billion
- Strong Sales Performance: Genmab reported that its multiple myeloma therapy DARZALEX achieved worldwide net sales of $3.96 billion in Q1, with U.S. sales contributing $2.208 billion and international markets generating $1.756 billion, indicating robust global demand for the product.
- Positive Market Reaction: Genmab's stock traded approximately 2% higher during pre-market hours, reflecting investor optimism regarding the company's sales growth and further solidifying its market position in the biopharmaceutical sector.
- Product Diversification: The sales figures include both intravenous and subcutaneous formulations, with the latter marketed in the U.S. as DARZALEX FASPRO, demonstrating the company's innovation in product forms to meet diverse patient needs.
- Industry Context: Despite pressures on the healthcare sector due to disruptions in the Middle East, Genmab stands out among oversold healthcare stocks above $10 billion, showcasing its product resilience and competitive strength in the market.
See More
Genmab Reports $3.964 Billion DARZALEX® Sales in Q1 2026
- Strong Sales Performance: In Q1 2026, Genmab reported worldwide net sales of DARZALEX® totaling $3.964 billion, with $2.208 billion from the U.S. and $1.756 billion from the rest of the world, indicating robust demand and growth potential for the product in global markets.
- Royalty Revenue: Genmab benefits from royalties on DARZALEX sales through its exclusive global licensing agreement with Johnson & Johnson, which not only provides a stable revenue stream but also strengthens its market position in the biopharmaceutical sector.
- Innovative Drug Development: Genmab is committed to improving the lives of cancer patients through innovative antibody medicines, showcasing its R&D capabilities and competitive edge in biotechnology, which is expected to drive future revenue growth.
- Global Market Presence: As an international biotechnology company, Genmab has established operations across North America, Europe, and Asia Pacific, and this global strategy enhances its market reach while providing ample opportunities for future expansion and growth.
See More
Safety Study of Rina-S and Bevacizumab Combination Therapy
- Clinical Trial Results: The RAINFOL™-01 trial demonstrated that the combination of Rina-S and bevacizumab was well-tolerated in 40 patients with advanced ovarian cancer, with no new safety signals, indicating potential for broader clinical treatment options.
- Adverse Event Analysis: Common treatment-emergent adverse events included nausea (80%), fatigue (67.5%), anemia (55%), and neutropenia (45%), providing critical safety data for future treatment regimens.
- Research Significance: Investigator Dr. Cara Mathews noted that the safety profile of Rina-S aligns with that of bevacizumab, potentially offering more effective disease control options for ovarian cancer patients, particularly in resistant cases.
- Future Development Directions: Genmab plans to further evaluate the efficacy of this combination therapy in the upcoming Phase 3 RAINFOL-04 trial, showcasing the company's ongoing commitment and innovative potential in ovarian cancer treatment.
See More
Corbus Secures FDA Alignment on CRB-701 Pathway
- FDA Progress: Corbus announced FDA alignment on its CRB-701 development pathway, paving the way for potential market opportunities in head and neck cancer treatment, which is expected to enhance its competitiveness in the biopharmaceutical industry.
- Market Opportunity Analysis: Analysts highlight that CRB-701's application in head and neck cancer could present significant upside potential, especially given the limited treatment options currently available, likely attracting more investor interest.
- Obesity Pipeline Outlook: In addition to CRB-701, Corbus is actively advancing its research in obesity treatment, with analysts suggesting that success in this pipeline could further elevate the company's overall valuation and market appeal.
- Strategic Implications: The FDA's alignment not only provides crucial regulatory support for Corbus but may also expedite its product launch process, positioning the company favorably in the competitive biopharmaceutical landscape.
See More
Genmab Major Shareholder Announcement
- Shareholder Ownership: As of March 27, 2026, Orbis Investment Management Limited controls 3,205,763 shares in Genmab A/S, representing 4.99% of the company's share capital and voting rights, indicating its significant influence in corporate governance.
- Investment Management Background: Orbis Investment Management Limited is a well-known investment management firm, and its increased stake may impact Genmab's strategic decisions and market performance, reflecting investor confidence in the company's future growth.
- Company Overview: Established in 1999 and headquartered in Copenhagen, Denmark, Genmab focuses on improving the lives of cancer and serious disease patients through innovative antibody medicines, having received approvals for eight antibody drugs, showcasing its strong R&D capabilities.
- Clinical Pipeline Progress: Genmab is advancing a robust late-stage clinical pipeline aimed at delivering transformative medicines to patients, and with the growing demand for biopharmaceuticals, the company's market outlook appears promising.
See More
